To the first question, no.
To the second question, I was not party to the original call for proposals. I understand, through consultation with others at the Canadian Association for HIV Research, that economic sustainability was one of the features of that original call.
If I may add to that point, part of the reason that the explanation for cancellation made no sense to me was that to say we have production capacity for small lots for early clinical discovery and development and that it's merely provided by commercial capacity does not address the issue of discovery and invention, simply because commercial goods manufacturing facilities are out of reach of discovery. The market for commercial production facilities is corporate. We don't get publicly funded grants to contract out vaccine production for a university or investigator. That doesn't happen. It's a corporate level kind of capacity we're talking about. In my opinion, if we want the GLP and GMP capacity to address issues of discovery and invention, it's not going to be done in the industry sector.
So in answer to the second part, it made no sense to me, but you know....